-

Tempus to Report First Quarter 2026 Financial Results on May 5

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the first quarter ended March 31, 2026 on Tuesday, May 5, 2026.

The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers.

The live audio webcast will be accessible through the “Events” section of the Tempus Investor Relations website. For those unable to listen to the live broadcast, a recording will be available on the website following the call. Alternatively, the call can be accessed via the following:

Conference ID: 4294068
United States - New York: (646) 307-1963
USA & Canada - Toll-Free: (800) 715-9871
Live webcast: https://edge.media-server.com/mmc/p/rv7jv7ti

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit www.tempus.com.

Contacts

Tempus
Hanah Heintzelman
hanah.heintzelman@tempus.com

Industry:

Tempus AI, Inc.

NASDAQ:TEM
Release Versions
English

Contacts

Tempus
Hanah Heintzelman
hanah.heintzelman@tempus.com

More News From Tempus AI, Inc.

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ: PSNL). The acquisition will expand Tempus' capabilities in minimal residual disease (MRD) and enhance its ability to support patients from diagnosis and treatment selection, to recurrence and monitoring. Under the terms of the agreement, Persona...

Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service

CHICAGO--(BUSINESS WIRE)--Tempus, a technology company leading the adoption of AI to advance precision medicine, today highlighted results of the Articulate Pro study, published in Nature Digital Medicine, evaluating the use of AI to assist pathologists in prostate biopsy reporting. The study was a real-world evaluation of the Paige Prostate Suite, an integral part of the Tempus intelligent diagnostics ecosystem, and its integration into routine clinical workflows. AI-assisted review supported...

Tempus to Report Second Quarter 2026 Financial Results on July 30

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second quarter ended June 30, 2026, on Thursday, July 30, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The...
Back to Newsroom